FREQUENCY AND CHARACTERISTICS OF ADVERSE EVENTS ASSOCIATED WITH ANTI-TUBERCULOSIS DRUGS DURING THE TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS
- Authors
-
-
Tashpulatova Fatima Kudratovna
Associate Professor of the Department of Infectious Diseases, Pediatric Infectious Diseases, Phthisiology and Pulmonology, Doctor of Medical Sciences, Tashkent State Medical University
Author
-
- Keywords:
- Tuberculosis, drug-resistant tuberculosis, adverse drug reactions, anti-tuberculosis drugs, MDR-TB, pharmacovigilance.
- Abstract
-
Background: Drug-resistant pulmonary tuberculosis (DR-TB) remains one of the most significant challenges in global tuberculosis control. Treatment regimens for multidrug-resistant and extensively drug-resistant tuberculosis involve prolonged use of multiple anti-tuberculosis drugs, often resulting in adverse drug reactions (ADRs) that may affect treatment adherence and outcomes.
Objective: To assess the frequency, spectrum, and clinical characteristics of adverse events associated with anti-tuberculosis medications in patients receiving treatment for drug-resistant pulmonary tuberculosis.
Methods: A retrospective observational study was conducted involving 200 patients diagnosed with drug-resistant pulmonary tuberculosis. Adverse events were analyzed according to severity, affected organ systems, and implicated anti-tuberculosis drugs. - References
-
1.World Health Organization. Global Tuberculosis Report 2025. Geneva: World Health Organization; 2025. p. 1–245.
2.Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Clinical Infectious Diseases. 2023;76(5):889–903.
3.Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JW, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet. 2023;401(10388):1491–1502.
4.Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D’Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug-resistant tuberculosis. European Respiratory Journal. 2023;61(1):2201768. p. 1–13.
5.Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. The Lancet Infectious Diseases. 2024;24(2)–e58.
- Downloads
- Published
- 2026-06-08
- Issue
- Vol. 2 No. 6 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
